AcouBatt raises £1.1M to catch battery defects during manufacturing
What's the deal? London-based deeptech startup AcouBattDealroom has a profile for this one. Try Dealroom → has raised £1.1 million in pre-seed funding to develop its battery diagnostics technology and advance industrial pilots with manufacturers. Creator FundDealroom has a profile for this one. Try Dealroom → led the round, with Ada VenturesDealroom has a profile for this one. Try Dealroom → participating.
What does it do? Spun out of UCL VenturesDealroom has a profile for this one. Try Dealroom → and founded in 2025 by Dr Arthur Fordham and Chris Haoxin Xu, AcouBatt uses acoustic sensing and AI to monitor processes inside battery cells during manufacturing. The technology detects defects in real time that might otherwise go unnoticed.
Why now? The startup is targeting lithium-ion battery formation, when manufacturers have limited visibility into cells. That gap can cause production bottlenecks, high rejection rates, and hard-to-detect defects.
What's the endgame? By combining acoustic and electrochemical data, the technology can flag when formation is complete — potentially cutting formation time by up to 30% — and catch faults before a batch is finished. AcouBatt is also exploring uses in battery energy storage systems and, eventually, electric vehicles.
"Our technology opens the door for manufacturers to drastically cut waste, optimise their processes, and bring safer, better batteries to the market more quickly," said Xu, co-founder and commercial director.
What's next? AcouBatt's sensors are deployed at the UK Battery Industrialisation CentreDealroom has a profile for this one. Try Dealroom →, where it is benchmarking diagnostics ahead of a commercial rollout next year. The funding will expand its technical team, develop its AI models, and advance industrial pilots.
The signal: As batteries spread across infrastructure, EVs, and storage, diagnostics are emerging as a distinct layer of the supply chain. AcouBatt's bet is that manufacturers will pay for visibility they currently lack — from a cell's formation to the end of its working life.
Read more: Tech.eu
Image credit: AcouBatt
